drugset

drugset / Trial / NCT00567918

Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

NCT00567918 ↗

Phase 3 Completed 52 enrolled Astellas Pharma Inc

NaSingle-groupOpen-labelTreatment

Summary

To investigate the long-term efficacy and safety of FK506 ophthalmic suspension in patients with vernal keratoconjunctivitis

Timeline

Start: 2004-05
Primary completion: 2008-01
Completion: 2008-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tacrolimus	Small molecule	0.1 %	Other

Indications